Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw unusually large options trading activity on Monday. Traders purchased 47,875 call options on the company. This is an increase of 1,767% compared to the average daily volume of 2,564 call options.
In related news, major shareholder Perceptive Advisors Llc acquired 335,827 shares of the company’s stock in a transaction dated Monday, March 5th. The stock was bought at an average cost of $13.56 per share, with a total value of $4,553,814.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO William D. Baird III sold 10,000 shares of Amicus Therapeutics stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $14.72, for a total transaction of $147,200.00. Following the sale, the chief financial officer now directly owns 105,121 shares of the company’s stock, valued at $1,547,381.12. The disclosure for this sale can be found here. Insiders have sold a total of 207,870 shares of company stock valued at $3,066,112 over the last ninety days. 3.40% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the business. New York State Common Retirement Fund boosted its stake in shares of Amicus Therapeutics by 8.3% during the 2nd quarter. New York State Common Retirement Fund now owns 153,500 shares of the biopharmaceutical company’s stock valued at $1,546,000 after purchasing an additional 11,699 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Amicus Therapeutics by 3.1% during the 2nd quarter. Northern Trust Corp now owns 1,738,010 shares of the biopharmaceutical company’s stock valued at $17,502,000 after purchasing an additional 52,569 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Amicus Therapeutics by 5.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after purchasing an additional 430,486 shares in the last quarter. Parametric Portfolio Associates LLC bought a new stake in shares of Amicus Therapeutics during the 2nd quarter valued at about $282,000. Finally, Voya Investment Management LLC boosted its stake in shares of Amicus Therapeutics by 22.2% during the 2nd quarter. Voya Investment Management LLC now owns 66,073 shares of the biopharmaceutical company’s stock valued at $665,000 after purchasing an additional 11,991 shares in the last quarter.
Amicus Therapeutics (NASDAQ:FOLD) traded up $0.01 during mid-day trading on Wednesday, hitting $15.17. 7,937,537 shares of the company’s stock were exchanged, compared to its average volume of 3,710,000. Amicus Therapeutics has a 12-month low of $6.41 and a 12-month high of $17.40. The stock has a market capitalization of $2,520.00, a PE ratio of -18.06 and a beta of 1.59. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.60 and a quick ratio of 5.53.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.11). Amicus Therapeutics had a negative net margin of 769.03% and a negative return on equity of 71.06%. The firm had revenue of $14.73 million during the quarter, compared to analysts’ expectations of $14.50 million. research analysts expect that Amicus Therapeutics will post -1.26 EPS for the current fiscal year.
FOLD has been the topic of a number of analyst reports. Leerink Swann lifted their target price on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. Zacks Investment Research cut shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 19th. Cowen reiterated a “buy” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 10th. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, January 15th. Finally, Robert W. Baird set a $20.00 target price on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $19.06.
TRADEMARK VIOLATION WARNING: “Traders Buy Large Volume of Call Options on Amicus Therapeutics (FOLD)” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2018/03/14/traders-purchase-high-volume-of-call-options-on-amicus-therapeutics-fold.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.